{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:41:41Z","timestamp":1787380901634,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02955-6","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T17:02:12Z","timestamp":1708966932000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity"],"prefix":"10.1007","volume":"57","author":[{"given":"Jeffrey D.","family":"Sperry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletha","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa B.","family":"Brighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joli D.","family":"Fermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Spezzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-5750","authenticated-orcid":false,"given":"Jennifer A.","family":"Szwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"2955_CR1","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL (2020) Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017\u20132018. NCHS Data Br No 360. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db360.htm. Accessed August 29, 2021"},{"issue":"1","key":"2955_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","volume":"117","author":"W Ageno","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117(1):93\u2013102. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.709204","journal-title":"Circulation"},{"issue":"5","key":"2955_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/J.1538-7836.2009.03295.X","volume":"7","author":"L Steffen","year":"2009","unstructured":"Steffen L, Cushman M, Peacock J et al (2009) Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J Thromb Haemost 7(5):746\u2013751. https:\/\/doi.org\/10.1111\/J.1538-7836.2009.03295.X","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2955_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/OBY.2009.92","volume":"17","author":"C Kabrhel","year":"2009","unstructured":"Kabrhel C, Varraso R, Goldhaber S, Rimm E, Camargo C (2009) Prospective study of BMI and the risk of pulmonary embolism in women. Obesity 17(11):2040\u20132046. https:\/\/doi.org\/10.1038\/OBY.2009.92","journal-title":"Obesity"},{"issue":"19","key":"2955_CR5","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.109.863241","volume":"120","author":"M Severinsen","year":"2009","unstructured":"Severinsen M, Kristensen S, Johnsen S, Dethlefsen C, Tj\u00f8nneland A, Overvad K (2009) Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation 120(19):1850\u20131857. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.863241","journal-title":"Circulation"},{"issue":"2","key":"2955_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/RTH2.12178","volume":"3","author":"S Moll","year":"2019","unstructured":"Moll S, Crona DJ, Martin K (2019) Direct oral anticoagulants in extremely obese patients: OK to use? Res Pract Thromb Haemost 3(2):152\u2013155. https:\/\/doi.org\/10.1002\/RTH2.12178","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2955_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/J.CHEST.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl E, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315\u2013352. https:\/\/doi.org\/10.1016\/J.CHEST.2015.11.026","journal-title":"Chest"},{"issue":"19","key":"2955_CR8","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/BLOODADVANCES.2020001830","volume":"4","author":"T Ortel","year":"2020","unstructured":"Ortel T, Neumann I, Ageno W et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693\u20134738. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020001830","journal-title":"Blood Adv"},{"issue":"24","key":"2955_CR9","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMOA0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEJM 361(24):2342\u20132352. https:\/\/doi.org\/10.1056\/NEJMOA0906598","journal-title":"NEJM"},{"issue":"7","key":"2955_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004450","journal-title":"Circulation"},{"issue":"9","key":"2955_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMOA1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. NEJM 369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMOA1302507","journal-title":"NEJM"},{"issue":"26","key":"2955_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMOA1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz S, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. NEJM 363(26):2499\u20132510. https:\/\/doi.org\/10.1056\/NEJMOA1007903","journal-title":"NEJM"},{"issue":"5","key":"2955_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1055\/a-1588-9155","volume":"122","author":"T Wang","year":"2022","unstructured":"Wang T, Carrier M, Fournier K, Siegal D, Le Gal G, Delluc A (2022) Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis. Thromb Haemost 122(5):830\u2013841. https:\/\/doi.org\/10.1055\/a-1588-9155","journal-title":"Thromb Haemost"},{"issue":"4","key":"2955_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/J.JACC.2013.07.104","volume":"63","author":"PA Reilly","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63(4):321\u2013328. https:\/\/doi.org\/10.1016\/J.JACC.2013.07.104","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2955_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/BCP.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76(6):908\u2013916. https:\/\/doi.org\/10.1111\/BCP.12114","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2955_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47(2):218\u2013226. https:\/\/doi.org\/10.1177\/0091270006296058","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"2955_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","volume":"50","author":"W Mueck","year":"2012","unstructured":"Mueck W, Lensing AWA, Agnelli G, D\u00e9cousus H, Prandoni P, Misselwitz F (2012) Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675\u2013686. https:\/\/doi.org\/10.2165\/11595320-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2955_CR18","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","volume":"6","author":"M Kushnir","year":"2019","unstructured":"Kushnir M, Choi Y, Eisenberg R et al (2019) Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 6(7):e359\u2013e365. https:\/\/doi.org\/10.1016\/S2352-3026(19)30086-9","journal-title":"Lancet Haematol"},{"issue":"2","key":"2955_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/S11239-020-02199-0","volume":"51","author":"OS Costa","year":"2020","unstructured":"Costa OS, Beyer-Westendorf J, Ashton V et al (2020) Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. J Thromb Thrombolysis 51(2):349\u2013358. https:\/\/doi.org\/10.1007\/S11239-020-02199-0","journal-title":"J Thromb Thrombolysis"},{"key":"2955_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/J.THROMRES.2019.08.021","volume":"182","author":"A Spyropoulos","year":"2019","unstructured":"Spyropoulos A, Ashton V, Chen Y, Wu B, Peterson E (2019) Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs. Thromb Res 182:159\u2013166. https:\/\/doi.org\/10.1016\/J.THROMRES.2019.08.021","journal-title":"Thromb Res"},{"issue":"4","key":"2955_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1060028019886092","volume":"54","author":"IJ Perales","year":"2019","unstructured":"Perales IJ, Agustin KS, DeAngelo J, Campbell AM (2019) Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann Pharmacother 54(4):344\u2013350. https:\/\/doi.org\/10.1177\/1060028019886092","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2955_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/JCM10020200","volume":"10","author":"A Cohen","year":"2021","unstructured":"Cohen A, Sah J, Lee T et al (2021) Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity. J Clin Med 10(2):200. https:\/\/doi.org\/10.3390\/JCM10020200","journal-title":"J Clin Med"},{"issue":"4","key":"2955_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1160\/TH16-02-0087\/ID\/OR0087-9","volume":"116","author":"M Di Nisio","year":"2016","unstructured":"Di Nisio M, Vedovati MC, Riera-Mestre A et al (2016) Treatment of venous thromboembolism with rivaroxaban in relation to body weight: a sub-analysis of the EINSTEIN DVT\/PE studies. Thromb Haemost 116(4):739\u2013746. https:\/\/doi.org\/10.1160\/TH16-02-0087\/ID\/OR0087-9","journal-title":"Thromb Haemost"},{"issue":"6","key":"2955_CR24","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/S12325-021-01716-8","volume":"38","author":"A Cohen","year":"2021","unstructured":"Cohen A, Pan S, Byon W, Ilyas B, Taylor T, Lee T (2021) Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Adv Ther 38(6):3003\u20133018. https:\/\/doi.org\/10.1007\/S12325-021-01716-8","journal-title":"Adv Ther"},{"issue":"4","key":"2955_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/EJH.13471","volume":"105","author":"WE Wysokinski","year":"2020","unstructured":"Wysokinski WE, Froehling DA, Houghton DE et al (2020) Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. Eur J Haematol 105(4):484\u2013494. https:\/\/doi.org\/10.1111\/EJH.13471","journal-title":"Eur J Haematol"},{"issue":"3","key":"2955_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/PHAR.2369","volume":"40","author":"JC Coons","year":"2020","unstructured":"Coons JC, Albert L, Bejjani A, Iasella CJ (2020) Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism. Pharmacotherapy 40(3):204\u2013210. https:\/\/doi.org\/10.1002\/PHAR.2369","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2955_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/0897190019854578","volume":"34","author":"KG Aloi","year":"2021","unstructured":"Aloi KG, Fierro JJ, Stein BJ, Lynch SM, Shapiro RJ (2021) Investigation of direct-acting oral anticoagulants and the incidence of venous thromboembolism in patients weighing\u2009>\u2009=\u2009120 kg compared to patients weighing\u2009<\u2009120 kg. J Pharm Pract 34(1):64\u201369. https:\/\/doi.org\/10.1177\/0897190019854578","journal-title":"J Pharm Pract"},{"issue":"2","key":"2955_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/PHAR.2655","volume":"42","author":"A Crouch","year":"2022","unstructured":"Crouch A, Ng TH, Kelley D et al (2022) Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy 42(2):119\u2013133. https:\/\/doi.org\/10.1002\/PHAR.2655","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2955_CR29","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/JTH.15358","volume":"19","author":"K Martin","year":"2021","unstructured":"Martin K, Beyer-Westendorf J, Davidson B, Huisman M, Sandset P, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 19(8):1874\u20131882. https:\/\/doi.org\/10.1111\/JTH.15358","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2955_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/J.1538-7836.2005.01204.X","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/J.1538-7836.2005.01204.X","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2955_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J (2009) Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support. Biomed Inf 42(2):377\u2013381","journal-title":"Biomed Inf"},{"key":"2955_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor B et al (2019) The REDCap consortium: building an international community of software partners. Biomed Inf. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"Biomed Inf"},{"issue":"2","key":"2955_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D (2010) Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13(2):273\u2013277. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00671.x","journal-title":"Value Health"},{"issue":"2","key":"2955_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11239-022-02641-5","volume":"54","author":"M Williams","year":"2022","unstructured":"Williams M, Ahuja T, Raco V et al (2022) Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients. J Thromb Thrombolysis 54(2):219\u2013229. https:\/\/doi.org\/10.1007\/s11239-022-02641-5","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2955_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11239-020-02308-z","volume":"52","author":"D Dreucean","year":"2021","unstructured":"Dreucean D, Nguyen SN, Donahue KR, Salazar E, Ruegger MC (2021) Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban. J Thromb Thrombolysis 52(1):161\u2013169. https:\/\/doi.org\/10.1007\/s11239-020-02308-z","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2955_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11239-015-1317-0","volume":"41","author":"MB Streiff","year":"2016","unstructured":"Streiff MB, Agnelli G, Connors JM et al (2016) Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 41(1):32\u201367. https:\/\/doi.org\/10.1007\/s11239-015-1317-0","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2955_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1160\/TH16-07-0494","volume":"117","author":"J Trujillo-Santos","year":"2017","unstructured":"Trujillo-Santos J, Di Micco P, Dentali F et al (2017) Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 117(2):382\u2013389. https:\/\/doi.org\/10.1160\/TH16-07-0494","journal-title":"Thromb Haemost"},{"key":"2955_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fmed.2020.00107","volume":"7","author":"K Deng","year":"2020","unstructured":"Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y (2020) Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med 7:107. https:\/\/doi.org\/10.3389\/fmed.2020.00107","journal-title":"Front Med"},{"key":"2955_CR39","doi-asserted-by":"publisher","unstructured":"Essien UR, Holmes DN, Jackson LR 2nd, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE (2018) Association of race\/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation II. JAMA Cardiol 3(12):1174\u20131182. https:\/\/doi.org\/10.1001\/jamacardio.2018.3945","DOI":"10.1001\/jamacardio.2018.3945"},{"issue":"1","key":"2955_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11239-021-02587-0","volume":"54","author":"B Williams","year":"2022","unstructured":"Williams B, Saseen JJ, Trujillo T, Palkimas S (2022) Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome. J Thromb Thrombolysis 54(1):67\u201373. https:\/\/doi.org\/10.1007\/s11239-021-02587-0","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"2955_CR41","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365\u20131371. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"2955_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.thromres.2020.10.010","volume":"198","author":"Z Sayar","year":"2021","unstructured":"Sayar Z, Moll R, Isenberg D, Cohen H (2021) Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management. Thromb Res 198:213\u2013221. https:\/\/doi.org\/10.1016\/j.thromres.2020.10.010","journal-title":"Thromb Res"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02955-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02955-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02955-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:08:13Z","timestamp":1713442093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02955-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02955-6","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"4 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Investigational Review Board (IRB) of each participating institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Jennifer A. Szwak is a member of an advisory board for Baxter Pharmaceuticals. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}